2Mon·

$ABBV (+5.38%)
AbbVie Reports Phase 2 EMPOWER Trials For Emraclidine In Schizophrenia Miss Primary Endpoint; Treatment Well-Tolerated, Further Data Analysis Underway

$BMY (-0.1%) Bristol-Myers Squibb seems to benefits from this +13%

11 Comments

Sebastian B.@Baisse-Jumper

2Mon

Should it go down another 10%-15% at $ABBV: 🛒🛒🛒🛒

•

Iwas M.@SSIT

2Mon

If AbbVie goes down even further, I might spontaneously get in today ^^

•

Memo0606@Memo0606

2Mon

@SSIT swiss
think it's good for shopping

•

Iwas M.@SSIT

2Mon

@Memo0606 I was a fool and opted for Johnson & Johnson when both values were around 140€ 😭 This value has simply burned itself into me.

•

Memo0606@Memo0606

2Mon

@SSIT well $JNJ i think it's not bad there are just more dividends
I am also invested

•

Sebastian B.@Baisse-Jumper

2Mon

@Memo0606 Not even yet. $ABBV already has a higher dividend yield and growth is also better. Nevertheless, $JNJ is already a good share.

•

Thomas@WolfofNersingen

2Mon

Am in

•

Vertriebsliebhaber@Vertriebsliebhaber

2Mon

Hach, 30% at $BMY in 6 months. I can live with that 🥳😎

•

Saschko@WarrenamBuffet

2Mon

stupid :(

••

Stefan@Slucks87

2Mon

Gut :)

••

Proolix@Proolix

2Mon

Hm... in my overview AbbVie is shown with minus 20%. If I go to the share with minus 12% ... 🤷‍♀️ is this a known error or what is the reason for this? 🤷‍♀️

••